KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.

Jianxing He, Masahiro Tsuboi, Walter Weder, Ke-Neng Chen, Maximilian J Hochmair, Jin-Yuan Shih, Sung Yong Lee, Kang-Yun Lee, Nguyen Viet Nhung, Somcharoen Saeteng, Lunxu Liu, Ligang Xing, Nguyen Hoang Gia, Shuji Murakami, Yongtao Han, María Paz Saavedra, Seong Hoon Yoon, Carlos H A Teixeira, Carles Escriu, Alex Martinez-Marti, Collin M Blakely, Yasushi Yatabe, Sanja Dacic, Yuri Rukazenkov, Xiangning Huang, Anupriya Dayal, Jamie E Chaft, NeoADAURA Investigators

J Clin Oncol 43(26) 2875-2887

PMID40454705
PMCIDPMC12994480
DOI10.1200/JCO-25-00883
发表日期2025-06-02
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: Adjuvant osimertinib is the standard of care for patients with resected epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Neoadjuvant treatment could improve surgical and long-term outcomes. METHODS: In this randomized, controlled, phase III study, patients with resectable, EGFR-mutated, stage II-IIIB NSCLC were randomly assigned (1:1:1) to receive neoadjuvant osimertinib (80 mg orally once daily for ≥9 weeks) plus platinum-based chemotherapy (once every 3 weeks for three cycles), osimertinib monotherapy (for ≥9 weeks), or placebo plus platinum-based chemotherapy (control), followed by surgical resection. Adjuvant osimertinib was offered to eligible patients after completion of surgery. The primary end point was major pathologic response (MPR) by blinded central pathology review. Event-free survival (EFS) was a secondary end point. RESULTS: Overall, 358 patients were randomly assigned to receive osimertinib plus chemotherapy (121 patients), osimertinib monotherapy (117 patients), or placebo plus chemotherapy (120 patients). Osimertinib plus chemotherapy (MPR rate 26%) and osimertinib monotherapy (25%) demonstrated statistically significant improvement in the MPR rate versus placebo plus chemotherapy (2%), with corresponding odds ratios of 19.82 (95.002% CI, 4.60 to 85.33; P < .0001) and 19.28 (99.9% CI, 1.71 to 217.39; P < .0001), respectively. With 15% data maturity, the EFS rates at 12 months were 93%, 95%, and 83% with osimertinib plus chemotherapy, osimertinib monotherapy, and placebo plus chemotherapy, respectively. In the neoadjuvant period, grade ≥3 adverse events of any cause occurred in 36%, 13%, and 33% of patients with osimertinib plus chemotherapy, osimertinib monotherapy, and placebo plus chemotherapy, respectively. No new safety concerns were identified. CONCLUSION: Neoadjuvant osimertinib with or without chemotherapy demonstrated statistically significant improvement in the MPR rate over chemotherapy alone in patients with resectable, EGFR-mutated, stage II-IIIB NSCLC.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 4

Figure 4.. Event-Free Survival, According to Investigator Assessment. The figure shows Kaplan–Meier estimates of EFS among patients in the full analysis set. EFS was measured from the time of randomization. Tick marks indicate censored data, and the vertical lines indicate landmark analyses of EFS at 6- and 12-months following randomization. An event was defined as the first of the following: documented disease progression that precluded surgery or prevented completion of definitive surgery; disease recurrence or a new lesion, local or distant, post-surgery (a new primary malignancy, confirmed by pathology if clinically feasible, was not considered to be an EFS event); for patients who did not undergo surgery for reasons other than disease progression, documented disease progression after the neoadjuvant period; discovery upon attempting surgery that the surgery could not be completed due to disease progression; or death due to any cause. At the interim analysis of EFS, the median duration of follow-up for EFS in all patients was 14.3 (range, < 0.1 to 41.9), 18.3 (range, 2.1 to 41.9), and 14.3 (range, 1.7 to 41.8) months for the osimertinib-plus-chemotherapy, osimertinib-monotherapy, and placebo-plus-chemotherapy groups, respectively; the median duration of follow-up for EFS in censored patients was 15.9 (range, < 0.1 to 41.9), 18.3 (range, 2.2 to 41.9) and 18.8 months (range, 1.7 to 41.8) for each group, respectively. *A 99.8% CI for the HR is presented for the comparison of the osimertinib-plus-chemotherapy versus placebo-plus-chemotherapy; as a statistically significant improvement was not reached for this comparison (a p value < 0.002 was required to declare statistical significance), the treatment difference in EFS between the osimertinib-monotherapy group and the placebo-plus-chemotherapy group was not formally tested. † A 95% CI for the HR is presented for the comparison of osimertinib-monotherapy versus placebo-plus-chemotherapy. CI, confidence interval; EFS, event-free survival; HR, hazard ratio; NC, not calculable; NR, not reached.

Event-Free_Survival_According_to_Investigator_Assessment

Event-Free Survival

Figure 4 · Panel Event-Free_Survival_According_to_Investigator_Assessment

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel Event-Free_Survival_According_to_Investigator_Assessment 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 3:extreme upward reversal
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. CONSORT diagram. *Written informed consent received. † One patient who was not randomized due to screen failure was incorrectly categorized as site terminated in error ‡ Two patients allocated to osimertinib-plus-chemotherapy did not receive any neoadjuvant study treatment; one patient withdrew consent prior to dosing and one patient was withdrawn by the investigator. § Includes patients who completed both osimertinib/placebo and chemotherapy for the osimertinib-plus-chemotherapy and placebo-plus-chemotherapy groups, and patients who completed osimertinib for osimertinib-monotherapy group; a patient is considered to have completed chemotherapy if they had completed all the required chemotherapy study drugs. ¶ Surgery status was missing for one patient allocated to osimertinib-plus-chemotherapy. ‖ One patient in the osimertinib-plus-chemotherapy group and one patient in the placebo-plus-chemotherapy group did not undergo surgery due to ‘study discontinuation’. These patients did not enter the EFS follow-up period. **Limited to patients who underwent and completed surgery, and patients who did not have surgery/complete surgery for reasons other than PD; patients who did not undergo surgery owing to PD entered the survival follow-up period. †† In addition to patients who received sponsor-supplied adjuvant osimertinib, 5 patients received adjuvant osimertinib from a commercial supply, including two patients in the osimertinib-plus-chemotherapy group, one patient in the osimertinib-monotherapy group, and two patients in the placebo-plus-chemotherapy group. ‡‡ Includes patients who did not undergo surgery due to PD or patients whose planned surgery was not completed due to PD. §§ The safety analysis set includes all randomized patients who received at least one dose of any neoadjuvant study treatment. DCO, data-cutoff; EFS, event-free survival; PD, progressive disease.
非 KM Figure
Figure 2Figure 2.. Major Pathological Response, Assessed by Blinded Central Pathology Review. Pathological response is summarized based on the full analysis set and was assessed with the use of recommendations from the International Association for the Study of Lung Cancer (2020). Patients ≤10% residual viable tumor in the lung primary tumor at the time of resection were considered to have had a major pathological response. Patients also had to have a R0 margin result to be classified as responders. Patients who were not evaluable per blinded central pathology review were classified as non-responders. Panel A shows major pathological response results for the full analysis set. Panels B and C show forest plots of major pathological response in prespecified subgroups for the comparison of osimertinib-plus-chemotherapy versus placebo-plus-chemotherapy and osimertinib-monotherapy versus placebo-plus-chemotherapy, respectively. The size of the data points is proportional to the number of patients in each subgroup. Shading indicates the difference in MPR rates and 95% CI for the full analysis set (all randomized patients). Differences in the proportion of patients with major pathological response between treatment groups was not calculated for subgroups with < 10 responders (across the osimertinib-plus-chemotherapy and placebo-plus-chemotherapy groups, or across osimertinib-monotherapy and placebo-plus-chemotherapy groups). Disease stage was defined according to the AJCC Cancer Staging Manual (eight edition). AJCC, American Joint Committee on Cancer; CI, confidence interval; ctDNA, circulating tumor DNA; EGFR, epidermal growth factor receptor; Ex19del, exon 19 deletion, MPR, major pathological response; NA, not applicable; OR, odds ratio; WHO PS, World Health Organization performance status.
非 KM Figure
Figure 3Figure 3.. Depth of Pathological Response, Assessed by Blinded Central Pathology Review. Depth of pathological regression in the primary tumor is summarized based on patients who were evaluable per blinded central pathological review and assessed with the use of recommendations from the International Association for the Study of Lung Cancer (2020). The waterfall plots show the percentage of regression in tumor area with viable cells (percentage of residual viable tumor minus 100%) for each patient in the osimertinib-plus-chemotherapy group (Panel A), the osimertinib-monotherapy group (Panel B), and the placebo-plus-chemotherapy group (Panel C). Grey indicates patients classified as non-responders for major pathological response and pathological complete response, yellow indicates patients with major pathological response, and green indicates patients with pathological complete response (per the prespecified definitions of these endpoints used for the primary and secondary endpoint analyses). MPR, major pathological response; pCR, pathological complete response.
非 KM Figure